Laurus Labs Limited (LAURUSLABS) - Total Assets
Based on the latest financial reports, Laurus Labs Limited (LAURUSLABS) holds total assets worth Rs94.15 Billion INR (≈ $1.02 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Laurus Labs Limited service its debt to assess how comfortably operating cash covers total debt obligations.
Laurus Labs Limited - Total Assets Trend (2013–2025)
This chart illustrates how Laurus Labs Limited's total assets have evolved over time, based on quarterly financial data. See LAURUSLABS total equity for net asset value and shareholders' equity analysis.
Laurus Labs Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Laurus Labs Limited's total assets of Rs94.15 Billion consist of 46.4% current assets and 53.6% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs84.30 Million | 1.1% |
| Accounts Receivable | Rs20.41 Billion | 21.9% |
| Inventory | Rs19.37 Billion | 20.7% |
| Property, Plant & Equipment | Rs43.16 Billion | 46.2% |
| Intangible Assets | Rs193.20 Million | 0.2% |
| Goodwill | Rs2.46 Billion | 2.6% |
Asset Composition Trend (2013–2025)
This chart illustrates how Laurus Labs Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Laurus Labs Limited (LAURUSLABS) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Laurus Labs Limited's current assets represent 46.4% of total assets in 2025, a decrease from 47.0% in 2013.
- Cash Position: Cash and equivalents constituted 1.1% of total assets in 2025, up from 0.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is property, plant & equipment at 46.2% of total assets.
Laurus Labs Limited Competitors by Total Assets
Key competitors of Laurus Labs Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
Laurus Labs Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.32 | 1.19 | 1.22 |
| Quick Ratio | 0.68 | 0.58 | 0.57 |
| Cash Ratio | 0.02 | 0.01 | 0.00 |
| Working Capital | Rs10.16 Billion | Rs6.60 Billion | Rs3.84 Billion |
Laurus Labs Limited - Advanced Valuation Insights
This section examines the relationship between Laurus Labs Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.37 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 11.3% |
| Total Assets | Rs93.36 Billion |
| Market Capitalization | $10.58 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Laurus Labs Limited's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Laurus Labs Limited's assets grew by 11.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Laurus Labs Limited (2013–2025)
The table below shows the annual total assets of Laurus Labs Limited from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs93.36 Billion ≈ $1.01 Billion |
+11.31% |
| 2024-03-31 | Rs83.87 Billion ≈ $907.03 Million |
+9.49% |
| 2023-03-31 | Rs76.60 Billion ≈ $828.44 Million |
+9.94% |
| 2022-03-31 | Rs69.68 Billion ≈ $753.57 Million |
+21.17% |
| 2021-03-31 | Rs57.51 Billion ≈ $621.92 Million |
+53.34% |
| 2020-03-31 | Rs37.50 Billion ≈ $405.58 Million |
+12.58% |
| 2019-03-31 | Rs33.31 Billion ≈ $360.26 Million |
+10.42% |
| 2018-03-31 | Rs30.17 Billion ≈ $326.25 Million |
+13.69% |
| 2017-03-31 | Rs26.53 Billion ≈ $286.96 Million |
+15.21% |
| 2016-03-31 | Rs23.03 Billion ≈ $249.07 Million |
+24.98% |
| 2015-03-31 | Rs18.43 Billion ≈ $199.28 Million |
+44.73% |
| 2014-03-31 | Rs12.73 Billion ≈ $137.69 Million |
+80.98% |
| 2013-03-31 | Rs7.03 Billion ≈ $76.08 Million |
-- |
About Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It… Read more